3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
90
Triple Negative Breast Neoplasms
18
Stomach Neoplasms
14
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
5
Testicular Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Carcinoma, Hepatocellular
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms, Male
2
pCR Rate
1
Women With Primary Breast Cancer
1
Upper Tract Urothelial Carcinoma
1
Unilateral HER2 Positive Breast Cancer
1
Thymoma
1
Testicular Germ Cell Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Rare Tumour
1
Prostatic Neoplasms
1
Primary Breast Cancer
1
Interventions
cabazitaxel
3
Trastuzumab
3
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
ribociclib
1
pertuzumab
1
eribulin
1
Thiotepa
1
Taxes
1
Stem Cell Transplantation
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liquid Biopsy
1
Letrozole
1
Ipilimumab
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Gemcitabine
1
Fulvestrant
1
Epirubicin
1
Docetaxel
1
Denosumab
1
Circulating Tumor DNA
1
Cell-Free Nucleic Acids
1
CA-72-4 antigen
1
CA-19-9 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplastic Cells, Circulating
×
Epirubicin
×
Clear all
NCT04771871
2026-05-07
TARMAC
University College Hospital, Ibadan
Phase 2
Recruiting
42 enrolled